Buprenorphine Initiation
PreclinicalSmall molecule
Buprenorphine Initiation is one of 43 small molecule programs targeting Treatment. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Theo-Dur
PfizerPreclinical
Levulan
Sun Pharmaceutical Industries, Inc.Preclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Intuniv
PPromius Pharma, LLC
Preclinical
Crixivan
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Somavert
PPharmacia and Upjohn
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Buprenorphine Initiation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYale University